



Public Health
England

Protecting and improving the nation's health

Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.phe.gov.uk

Dr Russell Hope

Head of Bacteraemia and CDI Surveillance Section
NIS - Infectious Disease Surveillance & Control

29 May 2018

Ref number 40753

Dear Applicant

Re: Case mix adjustment of patients with intensive care unit acquired blood stream infections (ICU-BSIs), and wider monitoring. (PHE Caldicott Advisory Panel)

Thank you for your application, submitted for assessment under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002 to process patient identifiable information without consent.

The role of the PHE Caldicott Advisory Panel is to review applications submitted under these Regulations and to provide advice on whether an application should be supported and, if so, any relevant conditions.

The PHE Caldicott Advisory Panel makes a determination as to whether Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 applies to processing described in your application.

This letter of support **does not** indicate wider information governance compliance. All information assets in Public Health England should have an entry in the information asset register and be held in compliance with PHE Information Governance Policy which includes a risk assessment to the rights of data subjects.

This application was considered at the Review Panel meeting held on **16 May 2018**.

The PHE Caldicott Advisory Panel **supports** the proposal subject to compliance with the standard and specific conditions.

Under Regulation 7 of the Health Service (Control of Patient Information) Regulations 2002, the PHE Caldicott Guardian support is subject to submission of an annual review report showing that the application is still able to demonstrate the legal basis for processing Patient Confidential Data.

It is your responsibility to review data, report any changes (such as to the purpose or design of the proposed activity, or to security and confidentiality arrangements) and submit this report within 12 months from the Panel date.

An annual review should therefore be provided no later than **4 April 2019**.

If at any stage you no longer require support under the Regulations, please notify the Caldicott Office immediately.

Please do not hesitate to contact the Caldicott Office in the first instance if you need any further assistance (caldicott@phe.gov.uk).

Yours sincerely

Professor Anthony Kessel
PHE Caldicott Guardian

Proposal Title	Case mix adjustment of patients with intensive care unit acquired blood stream infections (ICU-BSIs), and wider monitoring						
Caldicott Review Panel reference number	40753						
Caldicott Review Panel Date	16/05/2018						
Information Asset Number	40753						
Information Asset Owner							
Information System Owner	Alan Johnson						
Legal basis for processing							
Classification of Regulation 3 support * (if Regulation 3 support approved)	<table border="1"> <tr> <td>a</td><td>Diagnosing communicable diseases and other risks to public health</td></tr> <tr> <td>b</td><td>Recognising trends in such diseases and risks</td></tr> <tr> <td>c</td><td>Controlling and preventing the spread of such diseases and risks</td></tr> </table>	a	Diagnosing communicable diseases and other risks to public health	b	Recognising trends in such diseases and risks	c	Controlling and preventing the spread of such diseases and risks
a	Diagnosing communicable diseases and other risks to public health						
b	Recognising trends in such diseases and risks						
c	Controlling and preventing the spread of such diseases and risks						
Opinion	Caldicott Review Panel supports the proposal						
Rationale	<ul style="list-style-type: none"> • The activity addresses a public health hazard • The data processing is appropriate and consistent with PHE policy • There is clear justification for not seeking consent due given the nature of the surveillance programme and the need to monitor and evaluate the incidence of ICU BSI and related infections • Opt out was not possible because it is a risk to the public's health 						
Recommendations (conditions of approval)							
Date	16/05/2018						
Approved by	Caldicott Advisory Panel under the auspices of the PHE Caldicott Guardian						

Next review	16/05/2019
-------------	------------